Endoscopic therapies for gallbladder drainage

Monica Saumoy; Julie Yang; Amit Bhatt; Juan Carlos Bucobo; Vinay Chandrasekhara; Andrew P. Copland; Kumar Krishnan; Nikhil A. Kumta; Ryan J. Law; Rahul Pannala; Mansour A. Parsi; Erik F. Rahimi; Guru Trikudanathan; Arvind J. Trindade; David R. Lichtenstein

doi:10.1016/j.gie.2021.05.031

Endoscopic therapies for gallbladder drainage

Monica Saumoy, Julie Yang, Amit Bhatt, Juan Carlos Bucobo, Vinay Chandrasekhara, Andrew P. Copland, Kumar Krishnan, Nikhil A. Kumta, Ryan J. Law, Rahul Pannala, Mansour A. Parsi, Erik F. Rahimi, Guru Trikudanathan, Arvind J. Trindade, David R. Lichtenstein

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Background and Aims: Endoscopic management of acute cholecystitis has expanded in patients who are considered nonoperative candidates. Traditionally managed with percutaneous cholecystostomy (PC), improvement in techniques and devices has led to increased use of endoscopic methods for gallbladder drainage. This document reviews technical aspects of endoscopic transpapillary gallbladder drainage (ET-GBD) and EUS-guided GBD (EUS-GBD) as well as their respective technical/clinical success and adverse event rates. Available comparative data are also reviewed among nonsurgical gallbladder drainage techniques (PC, ET-GBD, and EUS-GBD). Methods: The MEDLINE database was searched through March 2021 for relevant articles by using keywords including “acute cholecystitis,” “interventional EUS,” “percutaneous cholecystostomy,” “transpapillary gallbladder drainage,” “EUS-guided gallbladder drainage,” “lumen-apposing metal stent,” “gallbladder stenting,” and “endoscopic gallbladder drainage.” The manuscript was drafted by 2 authors and reviewed by members of the American Society for Gastrointestinal Endoscopy Technology Committee and subsequently by the American Society for Gastrointestinal Endoscopy Governing Board. Results: Multiple studies have demonstrated acceptable outcomes comparing PC and both endoscopic gallbladder drainage techniques, ET-GBD and EUS-GBD. Published data suggest that endoscopic gallbladder drainage techniques may be associated with lower rates of adverse events and improved quality of life. However, there are important clinical considerations for choosing among these treatment options, requiring a multidisciplinary and collaborative approach to therapeutic decision-making in these patients. Conclusions: The implementation of EUS-GBD and ET-GBD in high-risk surgical patients with acute cholecystitis may result in favorable outcomes when compared with PC. Further improvements in techniques and training should lead to more widespread acceptance and dissemination of these treatment options.

Original language	English (US)
Pages (from-to)	671-684
Number of pages	14
Journal	Gastrointestinal endoscopy
Volume	94
Issue number	4
DOIs	https://doi.org/10.1016/j.gie.2021.05.031
State	Published - Oct 2021

Bibliographical note

Funding Information:
The following authors disclosed financial relationships: M. Saumoy: Food and beverage compensation from Boston Scientific Corporation, Ethicon US, LLC, Allergan Inc, and AbbVie, Inc. J. Yang: Consultant for Olympus Corporation of the Americas and Cook Medical LLC; travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas, Cook Medical LLC, US Endoscopy, Boston Scientific Corporation, Conmed Corporation, Salix Pharmaceuticals, and AbbVie, Inc. A. Bhatt: Consultant for Lumendi LLC; patent for a commercial device licensed to Medtronic; food and beverage compensation from Lumendi LLC, Covidien LP, Boston Scientific Corporation, Olympus America Inc, and Shionogi Inc. J. Bucobo: Consultant for Cook Medical LLC; travel compensation from Cook Medical LLC and Olympus Corporation of the Americas; food and beverage compensation from Cook Medical LLC, Olympus Corporation of the Americas, Boston Scientific Corporation, AbbVie, Inc, Janssen Biotech, Inc, Steris Corporation, Ferring Pharmaceuticals Inc, Takeda Pharmaceuticals USA, Inc, Endogastric Solutions, Inc, Merck Sharp & Dohme Corporation, Dova Pharmaceuticals, Pfizer Inc, and Allergan Inc. V. Chandrasekhara: Consultant for Covidien LP; advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc; grant support from Cook Medical LLC; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. A. Copland: Education compensation from Salix Pharmaceauticals, Ltd. K. Krishnan: Consultant for Olympus Corporation of the Americas and Medtronic; has received travel compensation and food and beverage from Olympus Corporation of the Americas; has received food and beverage from Boston Scientific Corporation. N. Kumta: Consultant for Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc; travel compensation from Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc; food and beverage compensation from Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc, Fijufilm Medical Systems USA, Inc, Steris Corporation, ERBE USA Inc, Endogastric Solutions, and Conmed Corporation. R. Law: Consultant for Olympus America Inc and Medtronic; travel compensation from Olympus America Inc; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Apollo Endosurgery US, Inc; scientific advisory board for Nestle Health Sciences. M. Parsi: Travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas, Conmed Corporation, Salix Pharmaceuticals, AbbVie, Inc, Shionogi Inc, Shire North American Group Inc, and Boston Scientific Corporation. E. Rahimi: Food and beverage compensation from AbbVie, Inc, Boston Scientific Corporation, and Covidien LP. G. Trikudanathan: Consultant for Boston Scientific Corporation; travel compensation from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Cook Medical LLC. A. Trindade: Consultant for Olympus Corporation of the Americas, Pentax of America, Inc, and Gyrus ACMI, Inc; food and beverage compensation from Olympus Corporation of the Americas, Pentax of America, Inc, and Gyrus ACMI, Inc; travel compensation from Pentax of America, Inc, Gyrus ACMI, Inc, and Boston Scientific Corporation; research grant from NinePoint Medical, Inc. D. Lichtenstein: Consultant for Olympus Corporation of the Americas, Augmenix, Inc, and Boston Scientific Corporation; education compensation and travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas and Boston Scientific Corporation.

Publisher Copyright:
© 2021 American Society for Gastrointestinal Endoscopy

PubMed: MeSH publication types

Practice Guideline

Access

10.1016/j.gie.2021.05.031

OpenUrl availability

Full text

Cite this

@article{f02157257cef4c59a901cd2b1a0115ea,

title = "Endoscopic therapies for gallbladder drainage",

abstract = "Background and Aims: Endoscopic management of acute cholecystitis has expanded in patients who are considered nonoperative candidates. Traditionally managed with percutaneous cholecystostomy (PC), improvement in techniques and devices has led to increased use of endoscopic methods for gallbladder drainage. This document reviews technical aspects of endoscopic transpapillary gallbladder drainage (ET-GBD) and EUS-guided GBD (EUS-GBD) as well as their respective technical/clinical success and adverse event rates. Available comparative data are also reviewed among nonsurgical gallbladder drainage techniques (PC, ET-GBD, and EUS-GBD). Methods: The MEDLINE database was searched through March 2021 for relevant articles by using keywords including “acute cholecystitis,” “interventional EUS,” “percutaneous cholecystostomy,” “transpapillary gallbladder drainage,” “EUS-guided gallbladder drainage,” “lumen-apposing metal stent,” “gallbladder stenting,” and “endoscopic gallbladder drainage.” The manuscript was drafted by 2 authors and reviewed by members of the American Society for Gastrointestinal Endoscopy Technology Committee and subsequently by the American Society for Gastrointestinal Endoscopy Governing Board. Results: Multiple studies have demonstrated acceptable outcomes comparing PC and both endoscopic gallbladder drainage techniques, ET-GBD and EUS-GBD. Published data suggest that endoscopic gallbladder drainage techniques may be associated with lower rates of adverse events and improved quality of life. However, there are important clinical considerations for choosing among these treatment options, requiring a multidisciplinary and collaborative approach to therapeutic decision-making in these patients. Conclusions: The implementation of EUS-GBD and ET-GBD in high-risk surgical patients with acute cholecystitis may result in favorable outcomes when compared with PC. Further improvements in techniques and training should lead to more widespread acceptance and dissemination of these treatment options.",

author = "Monica Saumoy and Julie Yang and Amit Bhatt and Bucobo, {Juan Carlos} and Vinay Chandrasekhara and Copland, {Andrew P.} and Kumar Krishnan and Kumta, {Nikhil A.} and Law, {Ryan J.} and Rahul Pannala and Parsi, {Mansour A.} and Rahimi, {Erik F.} and Guru Trikudanathan and Trindade, {Arvind J.} and Lichtenstein, {David R.}",

note = "Funding Information: The following authors disclosed financial relationships: M. Saumoy: Food and beverage compensation from Boston Scientific Corporation, Ethicon US, LLC, Allergan Inc, and AbbVie, Inc. J. Yang: Consultant for Olympus Corporation of the Americas and Cook Medical LLC; travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas, Cook Medical LLC, US Endoscopy, Boston Scientific Corporation, Conmed Corporation, Salix Pharmaceuticals, and AbbVie, Inc. A. Bhatt: Consultant for Lumendi LLC; patent for a commercial device licensed to Medtronic; food and beverage compensation from Lumendi LLC, Covidien LP, Boston Scientific Corporation, Olympus America Inc, and Shionogi Inc. J. Bucobo: Consultant for Cook Medical LLC; travel compensation from Cook Medical LLC and Olympus Corporation of the Americas; food and beverage compensation from Cook Medical LLC, Olympus Corporation of the Americas, Boston Scientific Corporation, AbbVie, Inc, Janssen Biotech, Inc, Steris Corporation, Ferring Pharmaceuticals Inc, Takeda Pharmaceuticals USA, Inc, Endogastric Solutions, Inc, Merck Sharp & Dohme Corporation, Dova Pharmaceuticals, Pfizer Inc, and Allergan Inc. V. Chandrasekhara: Consultant for Covidien LP; advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc; grant support from Cook Medical LLC; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. A. Copland: Education compensation from Salix Pharmaceauticals, Ltd. K. Krishnan: Consultant for Olympus Corporation of the Americas and Medtronic; has received travel compensation and food and beverage from Olympus Corporation of the Americas; has received food and beverage from Boston Scientific Corporation. N. Kumta: Consultant for Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc; travel compensation from Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc; food and beverage compensation from Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc, Fijufilm Medical Systems USA, Inc, Steris Corporation, ERBE USA Inc, Endogastric Solutions, and Conmed Corporation. R. Law: Consultant for Olympus America Inc and Medtronic; travel compensation from Olympus America Inc; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Apollo Endosurgery US, Inc; scientific advisory board for Nestle Health Sciences. M. Parsi: Travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas, Conmed Corporation, Salix Pharmaceuticals, AbbVie, Inc, Shionogi Inc, Shire North American Group Inc, and Boston Scientific Corporation. E. Rahimi: Food and beverage compensation from AbbVie, Inc, Boston Scientific Corporation, and Covidien LP. G. Trikudanathan: Consultant for Boston Scientific Corporation; travel compensation from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Cook Medical LLC. A. Trindade: Consultant for Olympus Corporation of the Americas, Pentax of America, Inc, and Gyrus ACMI, Inc; food and beverage compensation from Olympus Corporation of the Americas, Pentax of America, Inc, and Gyrus ACMI, Inc; travel compensation from Pentax of America, Inc, Gyrus ACMI, Inc, and Boston Scientific Corporation; research grant from NinePoint Medical, Inc. D. Lichtenstein: Consultant for Olympus Corporation of the Americas, Augmenix, Inc, and Boston Scientific Corporation; education compensation and travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas and Boston Scientific Corporation. Publisher Copyright: {\textcopyright} 2021 American Society for Gastrointestinal Endoscopy",

year = "2021",

month = oct,

doi = "10.1016/j.gie.2021.05.031",

language = "English (US)",

volume = "94",

pages = "671--684",

journal = "Gastrointestinal endoscopy",

issn = "0016-5107",

publisher = "Mosby Inc.",

number = "4",

}

TY - JOUR

T1 - Endoscopic therapies for gallbladder drainage

AU - Saumoy, Monica

AU - Yang, Julie

AU - Bhatt, Amit

AU - Bucobo, Juan Carlos

AU - Chandrasekhara, Vinay

AU - Copland, Andrew P.

AU - Krishnan, Kumar

AU - Kumta, Nikhil A.

AU - Law, Ryan J.

AU - Pannala, Rahul

AU - Parsi, Mansour A.

AU - Rahimi, Erik F.

AU - Trikudanathan, Guru

AU - Trindade, Arvind J.

AU - Lichtenstein, David R.

N1 - Funding Information: The following authors disclosed financial relationships: M. Saumoy: Food and beverage compensation from Boston Scientific Corporation, Ethicon US, LLC, Allergan Inc, and AbbVie, Inc. J. Yang: Consultant for Olympus Corporation of the Americas and Cook Medical LLC; travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas, Cook Medical LLC, US Endoscopy, Boston Scientific Corporation, Conmed Corporation, Salix Pharmaceuticals, and AbbVie, Inc. A. Bhatt: Consultant for Lumendi LLC; patent for a commercial device licensed to Medtronic; food and beverage compensation from Lumendi LLC, Covidien LP, Boston Scientific Corporation, Olympus America Inc, and Shionogi Inc. J. Bucobo: Consultant for Cook Medical LLC; travel compensation from Cook Medical LLC and Olympus Corporation of the Americas; food and beverage compensation from Cook Medical LLC, Olympus Corporation of the Americas, Boston Scientific Corporation, AbbVie, Inc, Janssen Biotech, Inc, Steris Corporation, Ferring Pharmaceuticals Inc, Takeda Pharmaceuticals USA, Inc, Endogastric Solutions, Inc, Merck Sharp & Dohme Corporation, Dova Pharmaceuticals, Pfizer Inc, and Allergan Inc. V. Chandrasekhara: Consultant for Covidien LP; advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc; grant support from Cook Medical LLC; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. A. Copland: Education compensation from Salix Pharmaceauticals, Ltd. K. Krishnan: Consultant for Olympus Corporation of the Americas and Medtronic; has received travel compensation and food and beverage from Olympus Corporation of the Americas; has received food and beverage from Boston Scientific Corporation. N. Kumta: Consultant for Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc; travel compensation from Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc; food and beverage compensation from Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc, Fijufilm Medical Systems USA, Inc, Steris Corporation, ERBE USA Inc, Endogastric Solutions, and Conmed Corporation. R. Law: Consultant for Olympus America Inc and Medtronic; travel compensation from Olympus America Inc; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Apollo Endosurgery US, Inc; scientific advisory board for Nestle Health Sciences. M. Parsi: Travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas, Conmed Corporation, Salix Pharmaceuticals, AbbVie, Inc, Shionogi Inc, Shire North American Group Inc, and Boston Scientific Corporation. E. Rahimi: Food and beverage compensation from AbbVie, Inc, Boston Scientific Corporation, and Covidien LP. G. Trikudanathan: Consultant for Boston Scientific Corporation; travel compensation from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Cook Medical LLC. A. Trindade: Consultant for Olympus Corporation of the Americas, Pentax of America, Inc, and Gyrus ACMI, Inc; food and beverage compensation from Olympus Corporation of the Americas, Pentax of America, Inc, and Gyrus ACMI, Inc; travel compensation from Pentax of America, Inc, Gyrus ACMI, Inc, and Boston Scientific Corporation; research grant from NinePoint Medical, Inc. D. Lichtenstein: Consultant for Olympus Corporation of the Americas, Augmenix, Inc, and Boston Scientific Corporation; education compensation and travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas and Boston Scientific Corporation. Publisher Copyright: © 2021 American Society for Gastrointestinal Endoscopy

PY - 2021/10

Y1 - 2021/10

N2 - Background and Aims: Endoscopic management of acute cholecystitis has expanded in patients who are considered nonoperative candidates. Traditionally managed with percutaneous cholecystostomy (PC), improvement in techniques and devices has led to increased use of endoscopic methods for gallbladder drainage. This document reviews technical aspects of endoscopic transpapillary gallbladder drainage (ET-GBD) and EUS-guided GBD (EUS-GBD) as well as their respective technical/clinical success and adverse event rates. Available comparative data are also reviewed among nonsurgical gallbladder drainage techniques (PC, ET-GBD, and EUS-GBD). Methods: The MEDLINE database was searched through March 2021 for relevant articles by using keywords including “acute cholecystitis,” “interventional EUS,” “percutaneous cholecystostomy,” “transpapillary gallbladder drainage,” “EUS-guided gallbladder drainage,” “lumen-apposing metal stent,” “gallbladder stenting,” and “endoscopic gallbladder drainage.” The manuscript was drafted by 2 authors and reviewed by members of the American Society for Gastrointestinal Endoscopy Technology Committee and subsequently by the American Society for Gastrointestinal Endoscopy Governing Board. Results: Multiple studies have demonstrated acceptable outcomes comparing PC and both endoscopic gallbladder drainage techniques, ET-GBD and EUS-GBD. Published data suggest that endoscopic gallbladder drainage techniques may be associated with lower rates of adverse events and improved quality of life. However, there are important clinical considerations for choosing among these treatment options, requiring a multidisciplinary and collaborative approach to therapeutic decision-making in these patients. Conclusions: The implementation of EUS-GBD and ET-GBD in high-risk surgical patients with acute cholecystitis may result in favorable outcomes when compared with PC. Further improvements in techniques and training should lead to more widespread acceptance and dissemination of these treatment options.

AB - Background and Aims: Endoscopic management of acute cholecystitis has expanded in patients who are considered nonoperative candidates. Traditionally managed with percutaneous cholecystostomy (PC), improvement in techniques and devices has led to increased use of endoscopic methods for gallbladder drainage. This document reviews technical aspects of endoscopic transpapillary gallbladder drainage (ET-GBD) and EUS-guided GBD (EUS-GBD) as well as their respective technical/clinical success and adverse event rates. Available comparative data are also reviewed among nonsurgical gallbladder drainage techniques (PC, ET-GBD, and EUS-GBD). Methods: The MEDLINE database was searched through March 2021 for relevant articles by using keywords including “acute cholecystitis,” “interventional EUS,” “percutaneous cholecystostomy,” “transpapillary gallbladder drainage,” “EUS-guided gallbladder drainage,” “lumen-apposing metal stent,” “gallbladder stenting,” and “endoscopic gallbladder drainage.” The manuscript was drafted by 2 authors and reviewed by members of the American Society for Gastrointestinal Endoscopy Technology Committee and subsequently by the American Society for Gastrointestinal Endoscopy Governing Board. Results: Multiple studies have demonstrated acceptable outcomes comparing PC and both endoscopic gallbladder drainage techniques, ET-GBD and EUS-GBD. Published data suggest that endoscopic gallbladder drainage techniques may be associated with lower rates of adverse events and improved quality of life. However, there are important clinical considerations for choosing among these treatment options, requiring a multidisciplinary and collaborative approach to therapeutic decision-making in these patients. Conclusions: The implementation of EUS-GBD and ET-GBD in high-risk surgical patients with acute cholecystitis may result in favorable outcomes when compared with PC. Further improvements in techniques and training should lead to more widespread acceptance and dissemination of these treatment options.

UR - http://www.scopus.com/inward/record.url?scp=85111565650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111565650&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2021.05.031

DO - 10.1016/j.gie.2021.05.031

M3 - Article

C2 - 34344541

AN - SCOPUS:85111565650

SN - 0016-5107

VL - 94

SP - 671

EP - 684

JO - Gastrointestinal endoscopy

JF - Gastrointestinal endoscopy

IS - 4

ER -

Endoscopic therapies for gallbladder drainage

Abstract

Bibliographical note

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this